HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Single-dose i.v. Aldactone for congestive heart failure: a preliminary observation.

Abstract
Aldactone (200 mg potassium canrenoate i.v.) was given in a single dose as the sole drug to 30 patients with congestive heart failure (CHF). Of these patients 21 were unresponsive to routine treatment. Clinical improvement was observed in 18 of 30 patients (60%) within 6 h after Aldactone injection. Good diuretic effect (urine volume over 500 ml/6 h) was achieved in 14 patients, including 7 cases who responded dramatically (diuresis 700-1500 ml in 6 h). Plasma aldosterone concentrations before the injection of Aldactone were variable in individual patients. An analysis of their diuretic response to the Aldactone injection within 6 h showed that responders had significantly higher initial plasma aldosterone level (312 +/- 108 pg/ml) than non-responders (152 +/- 31 pg/ml) (p less than 0.02). The same tendency was observed if good or poor clinical effects were considered. Aldactone caused a slight increase in plasma potassium level (0.20 mEq/1) (p less than 0.025). Aldactone given in a single dose i.v. to patients with CHF is a potent drug and can produce a dramatic response in some individuals who are refractory to routine therapy. The beneficial effects of Aldactone could be seen within the first 6 h especially in patients with secondary aldosteronism.
AuthorsL Ceremuzyński, A Budaj, B Michorowski
JournalInternational journal of clinical pharmacology, therapy, and toxicology (Int J Clin Pharmacol Ther Toxicol) Vol. 21 Issue 8 Pg. 417-21 (Aug 1983) ISSN: 0174-4879 [Print] Germany
PMID6629545 (Publication Type: Journal Article)
Chemical References
  • Pregnadienes
  • Aldosterone
  • Canrenoic Acid
Topics
  • Aged
  • Aldosterone (blood)
  • Canrenoic Acid (administration & dosage)
  • Diuresis (drug effects)
  • Female
  • Heart Failure (drug therapy)
  • Humans
  • Injections, Intravenous
  • Male
  • Middle Aged
  • Pregnadienes (administration & dosage)
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: